A bioinformatics spinoff company from Case Western Reserve University has reached an exclusive option agreement to license technology from the university.The company, NeoProteomics, was co-founded by Mark Chance, director of Case Center for Proteomics and Bioinformatics. NeoProteomics focuses on the identification and validation of biomarkers, proteins in the blood that can indicate the presence of [...]

Case Western Reserve University’s top technology transfer official is resigning from the university to start a new technology transfer and venture development consulting firm. Mark Coticchia’s resignation is effective April 1. He joined Case in 2001.

Medical imaging technology company Bioptigen, based in Research Triangle Park, North Carolina, has received a warning that its hand-held imaging device for the eye is being marketed beyond the scope of its 510(k) clearance.

Researchers from Cleveland Clinic and Case Western Reserve University have received a three-year, $3 million grant to study HIV and the body’s response in autoimmune diseases.

Case Western Reserve University School of Medicine has received a $7.8 million federal grant to continue a long-term study into bipolar disorders in children.

Stem cell company Athersys completed a study showing its technology could hold therapeutic benefits in treating spinal cord injuries. Researchers found that administering Athersys’ MultiStem technology to rodents with spinal injuries reduced inflammation and promoted the regrowth of neurons.

A new Alzheimer’s disease biomarker test developed by Durham, North Carolina-based Zinfandel Pharmaceuticals is licensed by Takeda Pharmaceutical Co. in a deal worth up to $87 million.

Case Western Reserve University has received its largest-ever grant for eye research — $10 million over five years to study retinal disease.

Though the tragic death of noted Alzheimer’s researcher Dr. Mark Smith has silenced the voice of one of the leading critics of the so-called amyloid theory, Smith’s Case Western Reserve University colleagues expect to carry on his work.

Alzheimer’s disease researcher Mark Smith, CWRU School of Medicine professor, was considered a “renegade researcher” for the way he challenged drug companies’ assumptions and other conventional wisdom on Alzheimer’s. But his opinions were gaining increasing attention, though, particularly after the failure of Eli Lilly’s Alzheimer drug in August. He was 45.